FDA grants orphan drug designation for Xorlo to treat autosomal dominant PKD

The FDA granted orphan drug designation for Xorlo, a drug from Xortx Therapeutics Inc. intended to treat autosomal dominant polycystic kidney disease, according to the press release.
“Orphan drug designation represents a major milestone for the company in pursuit of marketing approval for Xorlo, our proprietary formulation of oxypurinol, and the XRx-008 program for [autosomal dominant PKD] ADPKD,” Allen Davidoff, PhD, founder and CEO of Xortx Therapeutics Inc., said in the release.
Oxypurinol is a xanthine oxidase inhibitor (XOI) with the ability to inhibit the production of uric

The FDA granted orphan drug designation for Xorlo, a drug from Xortx Therapeutics Inc. intended to treat autosomal dominant polycystic kidney disease, according to the press release.
“Orphan drug designation represents a major milestone for the company in pursuit of marketing approval for Xorlo, our proprietary formulation of oxypurinol, and the XRx-008 program for [autosomal dominant PKD] ADPKD,” Allen Davidoff, PhD, founder and CEO of Xortx Therapeutics Inc., said in the release.
Oxypurinol is a xanthine oxidase inhibitor (XOI) with the ability to inhibit the production of uric